Top stories - GoINPHARMA
Sunday, 17 February 2019 - 17:37

Top stories

Zambon targets €100m acquisition in China and US

The CEO of Italy-based Zambon, Roberto Tascione, former head of BMS Italy, has reportedly said in an interview to Reuters that his group is seeking acquisitions in China and the US. The sectors targeted by the company are respiratory and…

Good latest quarter from BMS

Bristol-Myers Squibb today has published, before trading opened in Wall Street, its fourth-quarter 2018 results. The data show a robust growth, which in the latest quarter has yielded a sales of $6bn (+10% vs Q4 2017) with a net profit…

Drugmakers announce new price increase due to shortage of 120 drugs

WSJ has published an article analyzing the drug shortage emergency recently arisen in the US. As many as 120 drugs currently have availability issues, due to the supply restrictions for some active ingredients from China and some major “product recalls”…

The challenge of genetics: creating a new DNA

Researcher Floyd Romesberg has been surprising the scientific community for years with new results, starting from the idea of expanding the alphabet of human genome with two new letters. Indeed, as already known, the genetic heritage of each human being…

Abbott gains control of Cephea Technologies

Abbott has announced it has exercised its option to acquire Cephea Valve Technologies, a company focusing on developing and marketing artificial mitral valves. These valves are delivered through a vein in the leg, forgoing the need for open-heart surgery to…

Another executive leaves AstraZeneca

After Bahija Jallal, who few weeks ago stepped down as President of AstraZeneca’s subsidiary Medimmune, and Mark Malone, former portfolio strategy chief, the turn to leave Pascal Soriot’s company yesterday came for Sean Bohen, EVP and chief medical officer. In…

Exelixis: rising star in biotech sector

It is an excellent momentum for San Francisco-based biotech Exelixis, which has been granted a FDA approval for its therapy Cabometyx, for the treatment of liver cancer (HCC) in patients having received sorafenib without any effect. Cabometyx was already approved…

Takeda planning to divest Nycomed

The Financial Times has reported that Japan-based Takeda is exploring a sale of non-core assets worth $10bn in order to fund the GBP46bn acquisition of Shire, recently approved. The assets to be put up for sale include Nycomed, a Switzerland-based…

Why AbbVie is probably the 2019 biotech superstar

AbbVie, headquartered in Illinois, is considered the sleeping giant of the biotech sector by many analysts. AbbVie was established in 2013 as a spin off of Abbott Laboratories and was soon listed (Wall Street). After its IPO its shares increased…

After Pfizer, Sanofi becomes partner of German biotech BioNTech

US-based Pfizer last August entered into a $420m cooperation agreement with German-based biotech company BioNTech. Now the turn has come for Sanofi, which has expanded the cooperation started in 2015 with an investment of €80m in shares, making the biotech…

First analysis of the $74bn Bristol-Myers Squibb-Celgene deal

Markets were surprised yesterday as Bristol-Myers Squibb’s $74bn acquisition of Celgene was announced. The transaction is the most expensive ever performed in the pharma sector: it exceeds Takeda’s acquisition of Shire by some billions–the Japan-based group paid over $62bn for…

Bristol-Myers Squibb surprises everyone: Celgene acquired for $74bn

Bristol-Myers Squibb has surprised markets by announcing the acquisition of competitor Celgene for $74bn (with additional $18bn for debt): this is the largest acquisition ever in the pharma sector. BMS has valued Celgene at $102.43 per share, that is a…

First negative effects of anti-vaccine campaigns in Europe

Measles has returned to Europe in the last few years: the cases reported in 2018 more than doubled the 2017 figures, reaching their peak over the last 20 years. The increase in measles and other contagious diseases reflects the anti-vaccination…

The biotechs promising to slow down ageing

Unity Biotechnology is a biotech based in San Francisco, California, listed in May (Nasdaq), with the ambitious objective to develop treatments slowing down ageing and increasing patients’ life expectancy.  Unity Biotechnology’s targets are ageing cells, also referred to as zombie…

Novartis becomes shareholder in Israel-based biotech Ayala Pharmaceuticals

Novartis has confirmed its plan to become a leader in oncology, indeed some days ago it announced a cooperation agreement with Israel-based Ayala Pharmaceuticals (Rehovot). Ayala has developed a unique approach to genomically-defined cancers. The agreement covers the AL102 candidate…

Breakthrough in nanomolecular technologies for solid tumor treatment

The prestigious scientific journal Nature Biotechnology has published in its latest issue an article by researchers from the Arizona State University and the National Center for Nanoscience and Technology of the Chinese Academy of Sciences, who have reported an extraordinary…

Perrigo owes €1.6bn to Irish tax authorities

Irish tax authorities have enjoined multinational Perrigo, headquartered in Dublin, to pay €1.64bn in taxes related to multiple sclerosis drug Tysabri for the last 5 years. Perrigo has soon stated it wants to file an appeal against Irish Revenue Commissioners….

An analysis of new GSK-Pfizer’s new OTC JV

GlaxoSmithKline and Pfizer yesterday surprised markets by announcing the creation of a joint venture with each group’s Consumer Health divisions. The new entity will be a $10bn-revenue giant, with a 25% EBIT and a 7.3% market share in the world…